ReviewFood science & nutrition2025
Emerging Links Between Ferroptosis and Neurodegeneration: Implications for Disease Mechanisms and Nutraceutical Interventions.
Review in Food science & nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Fenofibrate mitigates microglial activation by reprogramming lipid metabolism and inhibiting ferroptosis.Molecular and cellular biochemistry · 2026Article
- Targeting Ferroptosis Pathways for Synaptic Protection in Sevoflurane-Induced Cognitive Impairment: A Nanomedicine Approach.CNS neuroscience & therapeutics · 2026Review
- Targeting ferroptosis in osteoporosis: mechanisms and natural products therapies.Frontiers in pharmacology · 2026Review
- Ferroptosis-Mediated Cell-Specific Damage: Molecular Cascades and Therapeutic Breakthroughs in Diabetic Retinopathy.Antioxidants (Basel, Switzerland) · 2025Review
- Recent advances in polysaccharides derived from theFrontiers in pharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A relatively recently identified type of controlled cell death termed 'ferroptosis' is driven by iron and characterized by reactive oxygen species (ROS) buildup and lipid peroxidation. This review explores the complex mechanisms underpinning ferroptosis and its potential effects on the onset and development of neurodegenerative diseases. The impact of lipid peroxides, glutathione/glutathione peroxidase 4 (GSH/GPX4), and iron metabolism-targeting small molecule inhibitors and the involvement of nucleic acids, proteins, and phytochemicals as inhibitors of ferroptosis will be discussed. Additionally, we explore the potential of ferroptosis as a therapeutic target for managing neurodegenerative disorders and address the challenges faced in clinical translation. The emerging research on novel drug delivery approaches and nanomaterial-based strategies for efficient ferroptosis inhibition is also described. In conclusion, this review provides a detailed overview of the complex landscape of ferroptosis, providing insights into its molecular mechanisms, inhibitors, and potential therapeutic applications. Understanding the multifaceted role of ferroptosis in disease pathogenesis will pave the way for developing innovative interventions to harness its therapeutic potential in various neurological conditions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.